JP2020033290A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020033290A5 JP2020033290A5 JP2018160272A JP2018160272A JP2020033290A5 JP 2020033290 A5 JP2020033290 A5 JP 2020033290A5 JP 2018160272 A JP2018160272 A JP 2018160272A JP 2018160272 A JP2018160272 A JP 2018160272A JP 2020033290 A5 JP2020033290 A5 JP 2020033290A5
- Authority
- JP
- Japan
- Prior art keywords
- aqueous composition
- solvate
- chlorhexidine
- salts
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- -1 Amino compound Chemical class 0.000 claims 4
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- 229960003260 chlorhexidine Drugs 0.000 claims 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims 4
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 3
- 229960003679 brimonidine Drugs 0.000 claims 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 229960002684 aminocaproic acid Drugs 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- 229940009662 edetate Drugs 0.000 claims 2
- 229960001484 edetic acid Drugs 0.000 claims 2
- 229940012017 ethylenediamine Drugs 0.000 claims 2
- 235000013922 glutamic acid Nutrition 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 229960003080 taurine Drugs 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018160272A JP2020033290A (ja) | 2018-08-29 | 2018-08-29 | 水性組成物 |
| JP2023025162A JP2023062143A (ja) | 2018-08-29 | 2023-02-21 | 水性組成物 |
| JP2024165820A JP2024169649A (ja) | 2018-08-29 | 2024-09-25 | 水性組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018160272A JP2020033290A (ja) | 2018-08-29 | 2018-08-29 | 水性組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023025162A Division JP2023062143A (ja) | 2018-08-29 | 2023-02-21 | 水性組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020033290A JP2020033290A (ja) | 2020-03-05 |
| JP2020033290A5 true JP2020033290A5 (enExample) | 2021-07-26 |
Family
ID=69667062
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018160272A Pending JP2020033290A (ja) | 2018-08-29 | 2018-08-29 | 水性組成物 |
| JP2023025162A Pending JP2023062143A (ja) | 2018-08-29 | 2023-02-21 | 水性組成物 |
| JP2024165820A Pending JP2024169649A (ja) | 2018-08-29 | 2024-09-25 | 水性組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023025162A Pending JP2023062143A (ja) | 2018-08-29 | 2023-02-21 | 水性組成物 |
| JP2024165820A Pending JP2024169649A (ja) | 2018-08-29 | 2024-09-25 | 水性組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP2020033290A (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1010024B (el) * | 2020-05-06 | 2021-06-01 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη |
| WO2022075472A1 (ja) * | 2020-10-09 | 2022-04-14 | アイ・セラピーズ・エル・エル・シー | ブリモニジンの液体製剤 |
| JP2022075651A (ja) * | 2020-11-06 | 2022-05-18 | 千寿製薬株式会社 | 眼科用液体製剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004073708A1 (en) * | 1998-12-17 | 2004-09-02 | Dean Thomas R | Brinzolamide and brimonidine for treating ocular conditions |
| WO2008024846A2 (en) * | 2006-08-25 | 2008-02-28 | Allergan, Inc. | Brimonidine and timolol compositions |
| CA3099517C (en) * | 2012-07-13 | 2022-04-26 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3179982B1 (en) * | 2014-07-28 | 2023-07-19 | Sun Pharma Advanced Research Company Ltd | Method of increasing bioavailability and/or prolonging ophthalmic action of a drug |
| MY178881A (en) * | 2014-12-12 | 2020-10-21 | Kowa Co | Novel aqueous composition |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| TWI751136B (zh) * | 2016-02-22 | 2022-01-01 | 日商參天製藥股份有限公司 | 含多佐胺與溴莫尼定之醫藥組成物 |
| JP6495379B2 (ja) * | 2016-06-15 | 2019-04-03 | 興和株式会社 | 水性の組成物 |
| JP6603785B2 (ja) * | 2017-12-08 | 2019-11-06 | 千寿製薬株式会社 | 水溶性高分子を含む水性液剤 |
| WO2019189720A1 (ja) * | 2018-03-30 | 2019-10-03 | 千寿製薬株式会社 | 水性液剤 |
-
2018
- 2018-08-29 JP JP2018160272A patent/JP2020033290A/ja active Pending
-
2023
- 2023-02-21 JP JP2023025162A patent/JP2023062143A/ja active Pending
-
2024
- 2024-09-25 JP JP2024165820A patent/JP2024169649A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006378B (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| JP2017222654A5 (enExample) | ||
| JP2018531941A5 (enExample) | ||
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| SA521422143B1 (ar) | 15-pgdh مثبط | |
| CN111601791A (zh) | Ezh2抑制剂及其药学上可接受的盐和多晶型物及其应用 | |
| DK3606909T3 (da) | Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid | |
| JP2016518359A5 (enExample) | ||
| EA201992771A1 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| MY201919A (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| JP2020033290A5 (enExample) | ||
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| JP2015537020A5 (enExample) | ||
| JP2008509166A5 (enExample) | ||
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| JP2016130266A5 (enExample) | ||
| JP2018516904A5 (enExample) | ||
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| CY1125198T1 (el) | Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς | |
| JP2015057437A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| JP2017521436A5 (enExample) | ||
| EA201691538A1 (ru) | Способ получения солей вортиоксетина |